Longeveron Inc. Share Price & Technical Analysis
LGVN · $0.82 (+13.89%)
Healthcare / Biotechnology
$0.82
+13.89%
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; comp…
Price chart
Bearish · Downtrend · Neutral
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$22.69M
P/E ratio
—
52W high
$1.80
52W low
$0.47
Volume
3,77,683
Beta
-0.32
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Longeveron Inc. share price today?
- Longeveron Inc. (LGVN) last traded around $0.82 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LGVN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LGVN. Download the app for real-time alerts.
- How can I analyze Longeveron Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.